The severe COVID-19 outcomes seen in MS patients do not appear attributable to an inherent immune dysfunction or an impaired antiviral response, but rather to MS-related disability and morbidity. That is the conclusion of the Italian MuSC-19 Study Group in its analysis of COVID-19 in MS patients (Sormani et al. Neurol Neuroimmunol Neuroinflamm 2022;9:e1105). Read More
Latest News
Slide deck: COVID-19 – Epidemiology in Canada (March 11, 2022)
March 11, 2022Summary of epidemiology, cases and mortality rate; Canada and world statistics.
Can COVID vaccination cause demyelination?
March 7, 2022At the 2022 ACTRIMS Forum, three groups presented data on acute demyelinating events following COVID-19 vaccination. Read More
ACTRIMS Forum 2022 – Update on anti-CD20s and vaccine response
March 1, 2022SPECIAL REPORT
Several studies presented at the ACTRIMS Forum 2022 provided some additional details on the COVID-19 vaccine response among MS patients treated with anti-CD20 therapies. The data suggest that vaccine response may differ somewhat among anti-CD20 agents, which may be related to the depth and/or duration of B cell suppression, the timing of vaccination and patient factors such as age. Read More